

## Special Issue

# Strategies for the Monitoring, Treatment, and Prevention of Mpox and Other Poxvirus Infections

### Message from the Guest Editors

Poxviruses can infect a remarkably wide range of hosts, making them a one-health concern for veterinary and human medicine worldwide. It is encouraging that some poxviral infections, are already vaccine-preventable or are close to being so.

Addressing epidemiologic, clinical, and immunologic aspects in animals and humans is necessary for understanding and improving the management of poxvirus infections, including actionable primary prevention.

**This Special Issue is dedicated to current and future strategies to enhance the monitoring, treatment, and prevention of poxviral diseases, with a special focus on, but not limited to, mpox.** Research may include the following:

- **Epidemiology and surveillance of poxvirus infections;**
- **Risk assessments of zoonotic spillover and the risk of epidemics requiring public health action;**
- **Studies of the immunogenicity, efficacy, and/or safety of poxvirus vaccines;**
- **Identification of poxvirus therapeutics and/or novel vaccine candidates;**
- **Public health and one-health approaches toward enhanced infection control;**
- **Investigation of vaccination coverage, hesitancy, and/or enhanced vaccine communication.**

---

### Guest Editors

Dr. Patrick Obermeier

Department of Infectious Diseases, St. Joseph Hospital Berlin  
Tempelhof, Berlin, Germany

Dr. Susanne Buder

Department of Dermatology and Venereology, Vivantes Hospital  
Neukölln, Berlin, Germany

---

### Deadline for manuscript submissions

31 August 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/203032](https://mdpi.com/si/203032)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).